Medicus Pharma Share Price: MDCX Stock Closed Up 15.35%

By Patrick Davis

Mar 21, 2025

4 min read

Medicus Pharma Share Price Soars: Medicus Pharma closed yesterday at $3.4950, up 15.35% from the previous close of $3.03. Find out all you need to know.

Medicus Pharma Nasdaq MDCX Stock Closed 15 Percent Up

Medicus Pharma Share Price Highlights: Medicus Pharma stock price climbed yesterday, 20 March 2025, by 15.35 %, according to Yahoo Finance1. The stock closed at $3.4950 per share. Investors should monitor Medicus Pharma's stock price closely in the coming days and weeks to see how it reacts to the news.

During its last trading day, Medicus Pharma opened at $3.0 and closed at $3.4950, reflecting a share price rise. The stock reached a high of $3.50 and a low of $2.90 during the day. Medicus Pharma has a market capitalization of $46.88M ($62.02M CAD), with a 52-week high of $4.99 and a low of $1.80. The trading volume, according to Yahoo Finance, was 32,363 shares traded.

#Medicus Pharma Live Updates: Shareholding information

Medicus Pharma has Institutional ownership of 59.2% and Insider ownership of 10.88%, with the CEO personally investing nearly $4M.

#Medicus Pharma Updates: Financial Performance

Medicus Pharma has delivered an Enterprise Value of $41.92M and a Price-to-Book value of 13.42.

#MDCX Stock Rating: The Consensus Analyst Rating Is Buy

Independent analysts, Maxim Group and Brookline Capital Markets have issued price targets of $10 & $122, reflecting potential upside based on clinical progress, expected market share, and regulatory approvals. These estimates assume successful commercialization by 2027 and represent a potential 4x return from the current share price of $2.90 on March 4, 2025. Their optimism stems from the company's ability to price its treatment at around $1,000, making it a cost-effective alternative to Mohs surgery, which typically ranges from $1,800 to $2,500 per procedure.

(Note: Analyst targets are based on projections and assumptions that may not materialize.)

#Medicus Pharma Interesting Updates: Stock Peers

Yesterday, Medicus Pharma shares increased by 15.35%, reaching a price of $3.4950. Among its biotech peers, 60 stocks gained, while 76 declined during the session. Meanwhile, the benchmark NASDAQ Index declined -0.33% during the session.

#About Medicus Pharma

Medicus Pharma Ltd. (NASDAQ: MDCX) is a biotech and life sciences company focused on advancing novel therapeutic assets through clinical development and commercialization. Its wholly owned subsidiary, SkinJect, is developing a dissolvable microneedle patch to treat basal cell carcinoma (BCC), the most common skin cancer worldwide. With clinical patents secured through 2035 and a Phase 2 trial underway, Medicus aims to expand its pipeline through acquisitions and partnerships3.

What You Need To Know About Medicus Pharma:

  • First-In-Class Microneedle Patch Technology: Non-invasive, painless, and cost-effective alternative to Mohs surgery, the current standard of care.

  • Breakthrough Treatment Option: 5 million+ basal cell carcinoma (BCC) cases diagnosed annually in the U.S.

  • SkinJect Market Opportunity: Medicus is targeting a $2B share of the $15B skin cancer market in North America3.

  • Projected Development Costs: $75M to $100M - substantially lower than the average cost of cancer treatment research and development of $648M4.

  • Pricing Advantage: Treatment price projected at ~$1,000 (E), offering a cost-effective alternative to Mohs surgery ($1,800–$2,500)2.

  • Analyst Confidence: Share price targets of $10 (Maxim Group) and $12 (Brookline Capital)2 - more than 240% to 300% upside based on a $2.90 closing price on 4 March 2025.
    (Note: Analyst targets are based on projections and assumptions that may not materialize).

  • Phase 2 Trial Progress: Over 50% of patients enrolled; positive interim data with 60% complete clinical clearance of the BCC lesions5.

  • Regulatory Pathway Advantage: Potential FDA Fast-Track designation.

  • Strong Financial Position: No long-term debt, $16M raised in 2024, sufficient cash for Phase 2 completion.

  • IP Protection: University-developed technology with patents secured through 2035.

#Growing Market Opportunity in Basal Cell Carcinoma

Basal cell carcinoma accounts for nearly five million new cases annually in the U.S., and this number is growing. A non-surgical treatment for basal cell carcinoma is projected to address a $7B+ market opportunity with high unmet medical need.

Innovative Cancer Treatment

Medicus Pharma’s SkinJect patch presents a viable and convenient alternative to the current standard of care for BCC, which is Mohs surgery. While Mohs surgery is effective, it is costly, painful and can leave aesthetic concerns.

SkinJect’s skin absorption delivery method directly targets cancer cells, minimizing systemic exposure and side effects. This also means there is the potential to prevent recurrence by stimulating an immunogenic reaction. Therefore, SkinJect could provide a complementary, non-invasive alternative to Mohs surgery.

A small, thumb-sized microneedle patch is applied to the skin over the BCC lesion. The patch is painless and easy to administer in a doctor’s office and can be applied during just three weekly 30-minute visits over 2 weeks. This has the potential to provide a simple and affordable solution to BCC patients seeking better treatment options. With over 5 million BCC cases diagnosed annually in the U.S., Medicus Pharma targets a $2 billion share of the $15 billion North American skin cancer market. Its SkinJect patch has projected development costs of $75–$100 million, far below the $648 million industry average4. Priced at around $1,000, it offers a cost-effective alternative to Mohs surgery ($1,800–$2,500)2.

Medicus Pharma (NASDAQ: MDCX) is positioned within a rapidly expanding global biotech industry valued at over $1.5 trillion. According to Grand View Research, the biotech market is projected to grow at a compound annual growth rate (CAGR) of 13.96% from 2023 to 20306, reflecting increased innovation, rising healthcare demands, and greater investment in life sciences. This growth environment creates a compelling backdrop for Medicus Pharma’s acquisition strategy, allowing the company to capitalize on high-potential opportunities within the sector.

Find out why this biotech company is gaining investor interest. Uncover the Stock Story

Get Free Investor Report

Related Articles:

Explore more on these topics:

Pharmaceuticals Biotechnology Investing Momentum Investing Healthcare

Important Notice And Disclaimer

PAID ADVERTISEMENT

This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Medicus Pharma to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of one hundred and seventy five thousand US dollars starting 3rd March 2025 for a period of 4 weeks until 28th March 2025 to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.

CHANGES IN SHARE TRADING AND PRICE

Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.

NO OFFER TO SELL OR BUY SECURITIES

This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.

INFORMATION

Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.

NO FINANCIAL ADVICE

The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.

FORWARD LOOKING STATEMENTS

This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.

INDEMNIFICATION/RELEASE OF LIABILITY

By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.

TERMS OF USE AND DISCLAIMER

By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact valuethemarkets.com to discontinue receiving future communications.

INTELLECTUAL PROPERTY

All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.

AUTHORS: VALUETHEMARKETS

valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above.